Norwegian pharmaceutical company Ultimovacs said it aimed to raise NOK700m ( $8.7m ) through an IPO 2022 to back its immunotherapy cancer drug. It also said it hoped to win approval to expand a UV1 trial investigating whether its UV1 vaccine candidate could tackle malignant melanoma alongside Ultimovacs ’s Keytruda cancer treatment. Ultimovacs has hired brokerages DNB Markets and ABG Sundal Collier for the IPO, but Arnesen declined to discuss valuation. DNB Markets has hired DNB Markets and Merck as brokers for the IPO and said while it forecast revenue from UV1 by 2022 , earlier income was expected from licensing deals with other companies.
Norwegian pharmaceutical company Ultimovacs said it aimed to raise NOK700m ( $8.7m ) through an IPO 2022 to back its immunotherapy cancer drug. It also said it hoped to win approval to expand a UV1 trial investigating whether its UV1 vaccine candidate could tackle malignant melanoma alongside Ultimovacs ’s Keytruda cancer treatment. DNB Markets has hired DNB Markets and Merck as brokers for the IPO and said while it forecast revenue from UV1 by 2022 , earlier income was expected from licensing deals with other companies.